A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease

Completed · Phase 2 · Has a placebo group

Conditions studied: Alzheimer Disease (AD)

In brief

The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).

Key facts

Study ID

NCT03518073

Run by

Eli Lilly and Company

People needed

360

Starts

2018-04-30

Expected to finish

2021-10-25

Last updated by the study team

2022-08-30

Who can join

Age: 60 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must have gradual and progressive change in memory function for >6 months.
• Participants must have a family member or close friend who is with you at least 10 hours per week and can attend study appointments.

You may not qualify if…

• Participants must not have significant neurological disease affecting the nervous system, other than AD, that affects cognition or may affect completion of the study.
• Participants must not have serious or unstable illness that could interfere with the analysis of the study or has a life expectancy <24 months.
• Participants must not have history of cancer within the last 5 years with the exception of certain types of skin, cervical, prostate, and other cancers that are not likely to recur or spread.
• Participants must not have serious risk for suicide.
• Participants must not have history of drug or alcohol use disorder within the last 2 years.
• Participants must not have multiple severe drug allergies
• Participants must not have HIV, Hepatitis B or Hepatitis C
• Participants must not be receiving gamma globulin (IgG) or intravenous immunoglobulin (IVIG) therapy

Where it is running

• Center for Neurosciences — Tucson, Arizona, United States
• Pharmacology Research Institute — Encino, California, United States
• Fullerton Neurology and Headache Center — Fullerton, California, United States
• Irvine Clinical Research Center — Irvine, California, United States
• Pharmacology Research Institute — Los Alamitos, California, United States
• National Research Institute - Huntington Park — Panorama City, California, United States
• Anderson Clinical Research — Redlands, California, United States
• Pacific Research Network — San Diego, California, United States
• Univ of California San Francisco — San Francisco, California, United States
• Syrentis Clinical Research — Santa Ana, California, United States
• New England Institute for Clinical Research — Stamford, Connecticut, United States
• JEM Research Institute — Atlantis, Florida, United States
• Julie B. Schwartzbard, MD, PA — Aventura, Florida, United States
• Quantum Laboratories Clinical Research — Deerfield Beach, Florida, United States
• Brain Matters Research — Delray Beach, Florida, United States
• Neuropsychiatric Research Center of Southwest Florida — Fort Myers, Florida, United States
• Infinity Clinical Research, LLC — Hollywood, Florida, United States
• VIN-Victor Faradji — Miami, Florida, United States
• Renstar Medical Research — Ocala, Florida, United States
• BioClinica Inc — Orlando, Florida, United States
• Progressive Medical Research — Port Orange, Florida, United States
• Brain Matters Research — Stuart, Florida, United States
• Infinity Clinical Research, LLC — Sunrise, Florida, United States
• Columbus Memory Center, PC — Columbus, Georgia, United States
• Banner Alzheimer's Institute — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.